Web Analytics

3 Latest Announced Rounds

  • $12,000,000
    Unknown

    3 Investors

    Hospital & Health Care
    Jun 4th, 2025
  • Undisclosed Amount
    Series A

    4 Investors

    Biotechnology Research
    Jun 4th, 2025
  • $21,000,000
    Unknown
    Software Development
    Jun 4th, 2025
$849.58M Raised in 57 Funding Rounds in the past 7 Days - View All

Funding Round Profile

ProJenX

start up
United States - New York, NY
  • 03/11/2023
  • Series A
  • $15,000,000

ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS. At the heart of ProJenX’s discoveries is an innovative, patient-specific, cell-based discovery platform that can be leveraged for the creation of additional transformative neuroscience medicines.


Related People

Stan AbelFounder

Stan Abel United States - New York, New York

N/A